{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T23:39:04Z","timestamp":1769211544300,"version":"3.49.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2018,5,15]],"date-time":"2018-05-15T00:00:00Z","timestamp":1526342400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1007\/s40273-018-0669-7","type":"journal-article","created":{"date-parts":[[2018,5,14]],"date-time":"2018-05-14T20:44:21Z","timestamp":1526330661000},"page":"1253-1261","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Economic Evaluation of Stiripentol for Dravet Syndrome: A Cost-Utility Analysis"],"prefix":"10.1007","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2501-1641","authenticated-orcid":false,"given":"Jesse","family":"Elliott","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bl\u00e1thnaid","family":"McCoy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2356-2300","authenticated-orcid":false,"given":"Tammy","family":"Clifford","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2289-9139","authenticated-orcid":false,"given":"George A.","family":"Wells","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3492-2268","authenticated-orcid":false,"given":"Doug","family":"Coyle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,5,15]]},"reference":[{"key":"669_CR1","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1177\/0883073807304207","volume":"22","author":"T Dur\u00e1-Trav\u00e9","year":"2007","unstructured":"Dur\u00e1-Trav\u00e9 T, Yoldi-Petri ME, Gallinas-Victoriano F. Epilepsy in children in Navarre, Spain: epileptic seizure types and epileptic syndromes. J Child Neurol. 2007;22:823\u20138.","journal-title":"J Child Neurol."},{"key":"669_CR2","doi-asserted-by":"publisher","first-page":"e1310","DOI":"10.1542\/peds.2015-1807","volume":"136","author":"YW Wu","year":"2015","unstructured":"Wu YW, Sullivan J, McDaniel SS, Meisler MH, Walsh EM, Li SX, et al. Incidence of Dravet syndrome in a US population. Pediatrics. 2015;136:e1310\u20135.","journal-title":"Pediatrics."},{"key":"669_CR3","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/B978-0-444-52891-9.00065-8","volume":"111","author":"C Dravet","year":"2013","unstructured":"Dravet C, Oguni H. Dravet syndrome (severe myoclonic epilepsy in infancy). Handb Clin Neurol. 2013;111:627\u201333.","journal-title":"Handb Clin Neurol."},{"key":"669_CR4","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s40272-016-0171-7","volume":"19","author":"A Wallace","year":"2016","unstructured":"Wallace A, Wirrell E, Kenney-Jung DL. Pharmacotherapy for Dravet syndrome. Paediatr Drugs. 2016;19:197\u2013208.","journal-title":"Paediatr Drugs."},{"key":"669_CR5","first-page":"CD010483","volume":"10","author":"F Brigo","year":"2015","unstructured":"Brigo F, Igwe SC. Antiepileptic drugs for the treatment of infants with severe myoclonic epilepsy. Cochrane Database Syst Rev. 2015;10:CD010483.","journal-title":"Cochrane Database Syst Rev."},{"key":"669_CR6","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1016\/S0140-6736(00)03157-3","volume":"356","author":"C Chiron","year":"2000","unstructured":"Chiron C, Marchand MC, Tran A, Rey E, D\u2019Athis P, Vincent J, et al. Stiripentol in severe myoclonic epilepsy in infancy: a randomised placebo-controlled syndrome-dedicated trial. STICLO Study Group. Lancet. 2000;356:1638\u201342.","journal-title":"Lancet."},{"issue":"Suppl. 8","key":"669_CR7","first-page":"155","volume":"43","author":"R Guerrini","year":"2002","unstructured":"Guerrini R, Tonnelier S, D\u2019Athis P, Rey E, Vincent J, Pons G, et al. Stiripentol in severe myoclonic epilepsy in infancy (SEMI): a placebo-controlled Italian trial [poster no. P496]. Epilepsia. 2002;43(Suppl. 8):155.","journal-title":"Epilepsia."},{"key":"669_CR8","volume-title":"Product monograph: Diacomit (stiripentol)","author":"Biocodex,","year":"2012","unstructured":"Biocodex, Product monograph: Diacomit (stiripentol). Gentilly: Biocodex; 2012."},{"key":"669_CR9","unstructured":"Common Drug Review. Pharmacoeconomic review report - Diacomit. Ottawa: CADTH; 2015. \n                    https:\/\/www.cadth.ca\/sites\/default\/files\/cdr\/pharmacoeconomic\/sr0360_diacomit_pe_report.pdf\n                    \n                  . Accessed 8 May 2018."},{"key":"669_CR10","volume-title":"Guidelines for the economic evaluation of health technologies: Canada","author":"CADTH","year":"2017","unstructured":"CADTH. Guidelines for the economic evaluation of health technologies: Canada. 4th ed. Ottawa: CADTH; 2017.","edition":"4"},{"key":"669_CR11","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.jval.2013.02.010","volume":"16","author":"D Husereau","year":"2013","unstructured":"Husereau D, Drummond M, Petrou S, Carswell C, Moher D, Greenberg D, et al. Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. Value Health. 2013;16:e1\u20135.","journal-title":"Value Health."},{"key":"669_CR12","unstructured":"National Institute for Health and Care Excellence (NICE). Appendix R: economic evaluation of AEDs used as monotherapy and adjunctive therapy in the treatment of children with focal seizures. London: NICE; 2012. pp. 55\u201376. \n                    https:\/\/www.nice.org.uk\/guidance\/cg137\/evidence\n                    \n                  . Accessed 8 May 2018."},{"key":"669_CR13","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.eplepsyres.2015.03.012","volume":"113","author":"Y Inoue","year":"2015","unstructured":"Inoue Y, Ohtsuka Y. Long-term safety and efficacy of stiripentol for the treatment of Dravet syndrome: a multicenter, open-label study in Japan. Epilepsy Res. 2015;113:90\u20137.","journal-title":"Epilepsy Res."},{"key":"669_CR14","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1177\/0272989X03255922","volume":"23","author":"AH Briggs","year":"2003","unstructured":"Briggs AH, Ades A, Price MJ. Probabilistic sensitivity analysis for decision trees with multiple branches: use of the Dirichlet distribution in a Bayesian framework. Med Decis Mak. 2003;23:341\u201350.","journal-title":"Med Decis Mak"},{"key":"669_CR15","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.eplepsyres.2016.10.006","volume":"128","author":"MS Cooper","year":"2016","unstructured":"Cooper MS, Mcintosh A, Crompton DE, McMahon JM, Schneider A, Farrell K, et al. Mortality in Dravet syndrome. Epilepsy Res. 2016;128:43\u20137.","journal-title":"Epilepsy Res."},{"key":"669_CR16","doi-asserted-by":"publisher","first-page":"3","DOI":"10.2165\/00019053-200725010-00002","volume":"25","author":"RL Fleurence","year":"2007","unstructured":"Fleurence RL, Hollenbeak CS. Rates and probabilities in economic modelling. Pharmacoeconomics. 2007;25:3\u20136.","journal-title":"Pharmacoeconomics."},{"key":"669_CR17","unstructured":"Verdian L, Oyee J, Heyes A, Tolley K, Yi Y. Eliciting preferences for health states associated with Lennox-Gastaut syndrome (LGS) [abstract no. 1.352]. 62nd meeting of the American Epilepsy Society; 5\u20139 Dec 2008; Seattle. \n                    https:\/\/www.aesnet.org\/meetings_events\/annual_meeting_abstracts\/view\/8833\n                    \n                  . Accessed 8 May 2018."},{"key":"669_CR18","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-15744-3","volume-title":"Cost effectiveness modelling for health technology assessment: a practical course","author":"R Edlin","year":"2015","unstructured":"Edlin R, Mccabe C, Hulme C, Hall P. Cost effectiveness modelling for health technology assessment: correlated parameters and the Cholesky decomposition. In: Edlin R, Mccabe C, Hulme C, Hall P, Wright J, editors. Cost effectiveness modelling for health technology assessment: a practical course. Cham: Springer; 2015."},{"key":"669_CR19","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1111\/j.1528-1157.1998.tb01164.x","volume":"39","author":"A Jacoby","year":"1998","unstructured":"Jacoby A, Buck D, Baker G, McNamee P, Graham-Jones S, Chadwick D. Uptake and costs of care for epilepsy: findings from a UK regional study. Epilepsia. 1998;39:776\u201386.","journal-title":"Epilepsia."},{"key":"669_CR20","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1111\/epi.13421","volume":"57","author":"P Jennum","year":"2016","unstructured":"Jennum P, Christensen J, Ibsen R, Kjellberg J. Long-term socioeconomic consequences and health care costs of childhood and adolescent-onset epilepsy. Epilepsia. 2016;57:1078\u201385.","journal-title":"Epilepsia."},{"key":"669_CR21","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.yebeh.2017.12.034","volume":"80","author":"MD Whittington","year":"2018","unstructured":"Whittington MD, Knupp KG, Vanderveen G, Kim C, Gammaitoni A, Campbell JD. The direct and indirect costs of Dravet syndrome. Epilepsy Behav. 2018;80:109\u201313.","journal-title":"Epilepsy Behav."},{"key":"669_CR22","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.yebeh.2014.03.014","volume":"34","author":"A Strzelczyk","year":"2014","unstructured":"Strzelczyk A, Schubert-Bast S, Reese JP, Rosenow F, Stephani U, Boor R. Evaluation of health-care utilization in patients with Dravet syndrome and on adjunctive treatment with stiripentol and clobazam. Epilepsy Behav. 2014;34:86\u201391.","journal-title":"Epilepsy Behav."},{"key":"669_CR23","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1111\/epi.13655","volume":"58","author":"BFM Wijnen","year":"2017","unstructured":"Wijnen BFM, van Mastrigt GAPG, Evers SMAA, Gershuni O, Lambrechts DAJE, Majoie MHJM, et al. A systematic review of economic evaluations of treatments for patients with epilepsy. Epilepsia. 2017;58:706\u201326.","journal-title":"Epilepsia."},{"key":"669_CR24","unstructured":"Common Drug Review. Stiripentol (Diacomit): for severe myoclonic epilepsy in infancy (Dravet syndrome): CDEC final recommendation. 2014. \n                    http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK349324\/\n                    \n                  . Accessed 8 May 2018."},{"key":"669_CR25","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1111\/j.1528-1167.2007.01466.x","volume":"49","author":"N Jett\u00e9","year":"2008","unstructured":"Jett\u00e9 N, Quan H, Faris P, Dean S, Li B, Fong A, et al. Health resource use in epilepsy: Significant disparities by age, gender, and aboriginal status. Epilepsia. 2008;49:586\u201393.","journal-title":"Epilepsia."},{"key":"669_CR26","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1111\/epi.13003","volume":"56","author":"JM Wilmshurst","year":"2015","unstructured":"Wilmshurst JM, Burman R, Gaillard WD, Cross JH. Treatment of infants with epilepsy: common practices around the world. Epilepsia. 2015;56:1033\u201346.","journal-title":"Epilepsia."},{"key":"669_CR27","doi-asserted-by":"publisher","first-page":"E787","DOI":"10.1503\/cmaj.081429","volume":"182","author":"AH Panju","year":"2010","unstructured":"Panju AH, Bell CM. Policy alternatives for treatments for rare diseases. CMAJ. 2010;182:E787\u201392.","journal-title":"CMAJ."},{"key":"669_CR28","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1503\/cmaj.050706","volume":"174","author":"JTR Clarke","year":"2006","unstructured":"Clarke JTR. Is the current approach to reviewing new drugs condemning the victims of rare diseases to death? A call for a national orphan drug review policy. CMAJ. 2006;174:189\u201390.","journal-title":"CMAJ."},{"key":"669_CR29","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1007\/978-90-481-9485-8_13","volume-title":"Rare Disease Epidemiology","author":"C McCabe","year":"2010","unstructured":"McCabe C, Edlin R, Round J. Economic considerations in the provision of treatments for rare diseases. In: de la Paz MP, Groft S, editors. Rare Disease Epidemiology, Chapter 13. Dordrecht: Springer; 2010. pp. 211\u201322."},{"key":"669_CR30","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1177\/0272989X14539731","volume":"34","author":"D Coyle","year":"2014","unstructured":"Coyle D, Cheung MC, Evans GA. Opportunity cost of funding drugs for rare diseases: the cost-effectiveness of eculizumab in paroxysmal nocturnal hemoglobinuria. Med Decis Mak. 2014;34:1016\u201329.","journal-title":"Med Decis Mak."},{"key":"669_CR31","first-page":"2013","volume-title":"Emergency medical services (EMS): 2013 OMBI performance measurement report","author":"Ontario Municipal Benchmarking Initiative (OMBI)","year":"2013","unstructured":"Ontario Municipal Benchmarking Initiative (OMBI). Emergency medical services (EMS): 2013 OMBI performance measurement report. Dundas: OMBI; 2013. p. 2013."}],"container-title":["PharmacoEconomics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40273-018-0669-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-018-0669-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-018-0669-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,14]],"date-time":"2019-05-14T20:39:39Z","timestamp":1557866379000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40273-018-0669-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,15]]},"references-count":31,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["669"],"URL":"https:\/\/doi.org\/10.1007\/s40273-018-0669-7","relation":{},"ISSN":["1170-7690","1179-2027"],"issn-type":[{"value":"1170-7690","type":"print"},{"value":"1179-2027","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,15]]},"assertion":[{"value":"15 May 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"No specific funding was received for this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Bl\u00e1thnaid McCoy is principal investigator in a study of cannabinoids for Dravet syndrome. Tammy Clifford is employed by CADTH (Canadian Agency for Drugs and Technologies in Health). She had no role in the review of stiripentol that was undertaken by the Common Drug Review. Jesse Elliott, George Wells, and Doug Coyle have no conflicts of interest to declare.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All data generated or analyzed during this study are included in this published article (and its online supplementary information files). The Markov model used in this analysis was provided for peer review.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability statement"}}]}}